Perrigo (PRGO) Total Non-Current Liabilities (2013 - 2026)
Perrigo (PRGO) reported Total Non-Current Liabilities of $4.5 billion for Q1 2026, up 3.82% year-over-year from $4.3 billion in Q1 2025, and down 2.18% quarter-over-quarter from $4.6 billion in Q4 2025.
Perrigo (PRGO) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Total Non-Current Liabilities data on file, last reported at $4.5 billion in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $4.5 billion, up 3.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 3.82% YoY), and the FY2025 annual result was $4.6 billion, up 7.07% from the prior year.
- Total Non-Current Liabilities retreated to $4.5 billion in Q1 2026 per PRGO's latest filing, from $4.6 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $5.2 billion in Q3 2024 and troughed at $4.3 billion in Q4 2024.
- A 5-year average of $4.7 billion and a median of $4.5 billion in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 37.32% in 2022, then fell 13.74% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $5.1 billion in 2022, then decreased by 11.99% to $4.5 billion in 2023, then decreased by 3.83% to $4.3 billion in 2024, then grew by 7.07% to $4.6 billion in 2025, then retreated by 2.18% to $4.5 billion in 2026.
- Business Quant data shows PRGO's Total Non-Current Liabilities at $4.5 billion in Q1 2026, $4.6 billion in Q4 2025, and $4.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn | 4.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 4.49 Bn |
| Dec 31, 2025 | 4.59 Bn |
| Sep 27, 2025 | 4.49 Bn |
| Jun 28, 2025 | 4.50 Bn |
| Mar 29, 2025 | 4.32 Bn |
| Dec 31, 2024 | 4.28 Bn |
| Sep 28, 2024 | 5.19 Bn |
| Jun 29, 2024 | 4.36 Bn |
| Mar 30, 2024 | 4.40 Bn |
| Dec 31, 2023 | 4.45 Bn |
| Sep 30, 2023 | 5.01 Bn |
| Jul 1, 2023 | 5.06 Bn |
| Apr 1, 2023 | 5.03 Bn |
| Dec 31, 2022 | 5.06 Bn |
| Oct 1, 2022 | 5.06 Bn |
| Jul 2, 2022 | 5.06 Bn |
| Apr 2, 2022 | 4.30 Bn |
| Dec 31, 2021 | 3.69 Bn |
| Oct 2, 2021 | 3.73 Bn |
| Jul 3, 2021 | 3.73 Bn |